To include your compound in the COVID-19 Resource Center, submit it here.

Xigris drotrecogin alfa: Phase IV, marketed

LLY began the placebo-controlled ADDRESS Phase IV trial in 11,000

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE